Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beijing Immunochina Medical Science & Technology Co., Ltd.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-70 years old, both men and women, and the survival period is more than 6 months.
At least one assessable focus, failure of previous multi-line treatment or stable condition after treatment.
Patients with melanoma confirmed by histopathology, patients with non-small cell lung cancer(squamous carcinoma) and head and neck squamous cell carcinoma.
The surgically removed pathological tissue can be used for immunohistochemical detection of target protein (paraffin section should be within 5 years), and the positive expression of target protein in line with pathological diagnosis (immunohistochemical staining + + or + + +).
Sufficient venous access for blood sampling and venous blood sampling, no contraindications for lymphocyte collection.
Liver and kidney function: alanine aminotransferase and aspartate aminotransferase \< 3 ULN, total bilirubin (TBIL) \< 1.5 ULN, serum creatinine (SCR) \< 2 ULN.
The subjects voluntarily joined the study, signed the informed consent form, had good compliance and cooperated with the follow-up.
You may not be if
Active hepatitis B or hepatitis C virus, HIV infection, or other unhealed active infections.
Patients with second tumor.
Patients previously treated with car-t cells.
Requiring long-term use of immunosuppressants for any reason.
Any serious and uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease and temporal arteritis.
Subjects with severe heart, lung, liver and kidney dysfunction or severe lung diseases.
Current systemic use of steroid cells (except for recent or current use of inhaled steroids).
Pregnant and lactating subjects.
Allergic to immunotherapy and related cells.
Subjects with a history of organ transplantation or waiting for organ transplantation.
After evaluation, the investigator considered that the subjects were unable or unwilling to comply with the requirements of the study protocol.
Clareo Health | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
